Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab.

Laura S Winterfield1, Alan Menter

  • 1Department of Dermatology, University of Texas Southwestern Medical School, Dallas, Texas, USA.

Dermatologic Therapy
|September 24, 2004
PubMed
Summary
This summary is machine-generated.

Infliximab effectively treats psoriasis and psoriatic arthritis by targeting tumor necrosis factor-alpha (TNF-alpha). This review covers infliximab

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

Dermatology and therapy·2023
Same author

Response to letter to the editor "It's time to consider a new topical algorithm for psoriasis".

Journal of the American Academy of Dermatology·2023
Same author

A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin.

JAAD case reports·2022
Same author

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

American journal of clinical dermatology·2022
Same author

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.

Dermatology and therapy·2022
Same journal

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.

Dermatologic therapy·2024
Same journal

Correction to "Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis".

Dermatologic therapy·2022
Same journal

A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib.

Dermatologic therapy·2022
Same journal

A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma.

Dermatologic therapy·2022
Same journal

High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts.

Dermatologic therapy·2022
Same journal

Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study.

Dermatologic therapy·2022
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Rheumatology

Background:

  • Psoriasis and psoriatic arthritis involve tumor necrosis factor-alpha (TNF-alpha).
  • TNF-alpha is a key pro-inflammatory cytokine in autoimmune diseases.

Purpose of the Study:

  • To review infliximab's efficacy and safety in treating psoriasis and psoriatic arthritis.
  • To discuss practical considerations for using infliximab in clinical settings.

Main Methods:

  • Review of clinical trial data on infliximab for psoriatic diseases.
  • Analysis of safety data from patients with other immune-mediated inflammatory disorders.

Main Results:

  • Infliximab shows rapid and substantial response in psoriasis and psoriatic arthritis.
  • TNF-alpha plays a significant role in the immunopathogenesis of these conditions.

    • Conclusions:

    • Infliximab is a valuable therapeutic option for psoriasis and psoriatic arthritis.
    • Considerations include patient selection, monitoring, cost, and combination therapies.